Global Cord Blood Corporation
CO was delisted on the 23rd of September, 2022.
2 hedge funds and large institutions have $64.5K invested in Global Cord Blood Corporation in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
16% more capital invested
Capital invested by funds: $55.7K → $64.5K (+$8.78K)
0% more funds holding
Funds holding: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$9.68K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
RhumbLine Advisers
Boston,
Massachusetts
| $64.3K | +$9.68K | +7,937 | +18% |
|
|
OA
2
Operose Advisors
Milwaukee,
Wisconsin
| $244 | – | – | – |
|
CO Hedge Fund Activity: Q4 2023 in Review
2 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Global Cord Blood Corporation (CO) for Q4 2023, worth a combined $64.5K — up 16% from $55.7K a quarter earlier.
Fund positioning in CO was balanced in Q4 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was RhumbLine Advisers, adding an estimated $9.68K.
- 2 institutional investors held Global Cord Blood Corporation (CO) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $64.5K of Global Cord Blood Corporation stock for Q4 2023, up 16% quarter-over-quarter.
- 0 funds opened new Global Cord Blood Corporation positions in Q4 2023 and 0 closed out.
- The largest Global Cord Blood Corporation buyer in Q4 2023 was RhumbLine Advisers, an estimated $9.68K added.
Based on aggregated 13F filings for Q4 2023.